ELAVL1 Role in Cell Fusion and Tunneling Membrane Nanotube Formations with Implication to Treat Glioma Heterogeneity

作者: Natalia Filippova , Louis B. Nabors

DOI: 10.3390/CANCERS12103069

关键词:

摘要: Homotypic and heterotypic cell fusions via permanent membrane temporal tunneling nanotube formations in the glioma microenvironment were recently documented vitro vivo mediate survival, plasticity, recurrence. Chronic inflammation, a hypoxic environment, aberrant mitochondrial function, ER stress due to unfolded protein accumulation upregulate fusion events, which leads tumor heterogeneity represents an adaptive mechanism promote survival plasticity cytotoxic, nutrient-deprived, mechanically stressed, inflammatory microenvironments. Cell is multistep process, consists of activation cellular response, autophagy formation, rearrangement cytoskeletal architecture areas cell-to-cell contacts, expression proinflammatory cytokines fusogenic proteins. The mRNA-binding ELAV-family HuR critical node, orchestrates architecture, overexpressed gliomas associated with poor prognosis treatment resistance. Our review provides link between role regulation potential suppression these processes by different classes inhibitors.

参考文章(129)
Koji Hase, Shunsuke Kimura, Hiroyuki Takatsu, Masumi Ohmae, Sayaka Kawano, Hiroshi Kitamura, Masatoshi Ito, Hiroshi Watarai, C. Clayton Hazelett, Charles Yeaman, Hiroshi Ohno, M-Sec promotes membrane nanotube formation by interacting with Ral and the exocyst complex. Nature Cell Biology. ,vol. 11, pp. 1427- 1432 ,(2009) , 10.1038/NCB1990
Nicole-Claudia Meisner, Martin Hintersteiner, Kurt Mueller, Roman Bauer, Jan-Marcus Seifert, Hans-Ulrich Naegeli, Johannes Ottl, Lukas Oberer, Christian Guenat, Serge Moss, Nathalie Harrer, Maximilian Woisetschlaeger, Christof Buehler, Volker Uhl, Manfred Auer, None, Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR Nature Chemical Biology. ,vol. 3, pp. 508- 515 ,(2007) , 10.1038/NCHEMBIO.2007.14
A. B. Mariotto, K. Robin Yabroff, Y. Shao, E. J. Feuer, M. L. Brown, Projections of the Cost of Cancer Care in the United States: 2010–2020 Journal of the National Cancer Institute. ,vol. 103, pp. 117- 128 ,(2011) , 10.1093/JNCI/DJQ495
Javier Mercapide, Germana Rappa, Aurelio Lorico, The intrinsic fusogenicity of glioma cells as a factor of transformation and progression in the tumor microenvironment International Journal of Cancer. ,vol. 131, pp. 334- 343 ,(2012) , 10.1002/IJC.26361
Christine Hostetter, Lauren A. Licata, Christina L. Costantino, Agnes Witkiewicz, Charles Yeo, Jonathan R Brody, Judith Clancy Keen, Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells Cancer Biology & Therapy. ,vol. 7, pp. 1496- 1506 ,(2008) , 10.4161/CBT.7.9.6490
Rongsheng Jin, Jagath R Junutula, Hugo T Matern, Karen E Ervin, Richard H Scheller, Axel T Brunger, Exo84 and Sec5 are competitive regulatory Sec6/8 effectors to the RalA GTPase. The EMBO Journal. ,vol. 24, pp. 2064- 2074 ,(2005) , 10.1038/SJ.EMBOJ.7600699
Sibani Sengupta, Byeong-Churl Jang, Ming-Tao Wu, Ji-Hye Paik, Henry Furneaux, Timothy Hla, The RNA-binding protein HuR regulates the expression of cyclooxygenase-2 Journal of Biological Chemistry. ,vol. 278, pp. 25227- 25233 ,(2003) , 10.1074/JBC.M301813200
Virginie Dormoy-Raclet, Anne Cammas, Barbara Celona, Xian Jin Lian, Kate van der Giessen, Marija Zivojnovic, Silvia Brunelli, Francesca Riuzzi, Guglielmo Sorci, Brian T. Wilhelm, Sergio Di Marco, Rosario Donato, Marco E. Bianchi, Imed-Eddine Gallouzi, HuR and miR-1192 regulate myogenesis by modulating the translation of HMGB1 mRNA. Nature Communications. ,vol. 4, pp. 2388- 2388 ,(2013) , 10.1038/NCOMMS3388
Amin Rustom, Rainer Saffrich, Ivanka Markovic, Paul Walther, Hans-Hermann Gerdes, Nanotubular Highways for Intercellular Organelle Transport Science. ,vol. 303, pp. 1007- 1010 ,(2004) , 10.1126/SCIENCE.1093133